Co-Diagnostics (FRA:C970) Cyclically Adjusted PS Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C970 Co-Diagnostics Inc FRA:C970
61 GF Score
Price €5.16
GF Value €7.47
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Co-Diagnostics  (FRA:C970) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Co-Diagnostics Cyclically Adjusted PS Ratio Related Terms


Co-Diagnostics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Cyclically Adjusted PS Ratio Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.18

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.35 0.18 0.06

FRA:C970 vs HSCS, NVNO, SINT: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Co-Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Cyclically Adjusted PS Ratio falls into.


FRA:C970
61GF Score
Co-Diagnostics Inc FRA:C970
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Co-Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Co-Diagnostics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.06/330.2130*330.2130
=0.060

Current CPI (Mar. 2026) = 330.2130.

Co-Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.005 244.955 0.007
201709 0.008 246.819 0.011
201712 0.007 246.524 0.009
201803 0.019 249.554 0.025
201806 0.022 251.989 0.029
201809 0.022 252.439 0.029
201812 0.023 251.233 0.030
201903 0.006 254.202 0.008
201906 0.097 256.143 0.125
201909 0.064 256.759 0.082
201912 0.177 256.974 0.227
202003 1.842 258.115 2.357
202006 21.963 257.797 28.132
202009 18.768 260.280 23.811
202012 22.979 260.474 29.131
202103 16.821 264.877 20.970
202106 22.913 271.696 27.848
202109 25.637 274.310 30.862
202112 18.055 278.802 21.384
202203 17.814 287.504 20.460
202206 4.392 296.311 4.895
202209 4.928 296.808 5.483
202212 1.342 296.797 1.493
202303 0.572 301.836 0.626
202306 0.189 305.109 0.205
202309 2.351 307.789 2.522
202312 3.320 306.746 3.574
202403 0.234 312.332 0.247
202406 2.458 314.175 2.583
202409 0.569 315.301 0.596
202412 0.138 315.605 0.144
202503 0.043 319.799 0.044
202506 0.128 322.561 0.131
202509 0.098 324.800 0.100
202512 0.140 324.054 0.143
202603 0.060 330.213 0.060

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Co-Diagnostics (FRA:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of €5.16 is trading 30.9% below its estimated GF Value™ of €7.47.

Key valuation signals for FRA:C970:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €7.47 vs. price of €5.16 (30.9% below fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the FRA:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
61GF Score

Get the complete analysis for FRA:C970

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.16
Price
€7.47
GF Value